The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit later.
We apologize for any inconvenience caused
Login  | Sign Up  |  Oriprobe Inc. Feed
China/Asia On Demand
Journal Articles
Laws/Policies/Regulations
Companies/Products
Clinical analysis of concurrent chemoradiotherapy for local advanced esophageal carcinoma
Author(s): 
Pages: 588-589
Year: Issue:  8
Journal: China Medicine

Keyword:  Esophageal carcinomaConcurrent chemoradiotherapyDocetaxelCisplatin;
Abstract: Objective To observe the efficacy and toxicity of concurrent ehemoradiotherapy combined with docetaxel and cisplatin for local advanced esophageal carcinoma. Methods Sixty-eight local advanced esophageal carcinoma patients were randomized into two groups. The group of control(n = 35) had radiotherapy only and experi-mental group (n = 33) received chemotherapy with 40 mg/m2 of docetaxei and 20 mg/m2 of cisplatin one time every week plus radiotherapy(DT 64Gy/2Gy/32Fx). Results The overall response rates of control group and experimental group was 45.7 % and 51.5% respectively, showing a significant difference (P = 0.04). The 1 year, 2year, 4year overall survival rate was 80.0%/57.1%, 28.6%/63.6%, 24.2%/12.1% respectively, also showing significant differences (P < 0.05). The difference of distant metastasis rate and the toxicity between two groups had no statistical differences (P >0.05). Conclusion The overall survival rate of local advanced esophageal carcinoma could be improred by ehemoradiotherapy.
Related Articles
loading...